Millions of patients and their loved ones are waiting for treatments, medical devices, and cures. Stakeholders in the public and private sectors will benefit tremendously from HARPA’s breakthroughs. Here are a few of the leaders who lend their support for HARPA.

Support for HARPA: 

Bob Wright_headshot.jpg

"The idea is to get projects completed, and then make them useful quickly. That’s a very different thing. That’s not what’s done today inside of health and human services. There’s nothing like that."

Bob Wright, Frmr Vice Chair GE & Chair NBCU; Founder, The Suzanne Wright Foundation; Co-Founder, Autism Speaks

Ling Official Photo.jpg

"It’s critical to create HARPA, because we have got to take advantage of all that has been accomplished to date and turn them into something tangible, such as a cure, or a treatment, and we have to do it as fast as possible."

Dr. Geoffrey Ling, Col. (Ret.) Prof. of Neurology, Johns Hopkins; Founder & Former Director, DARPA BTO

Dean Kamen.jpg

"Somebody’s got to de-risk it so that these big companies, A, have a high probability that it’ll work, and B, it’s not going to take ten years to find out. That’s what HARPA ought to be doing."

Dean Kamen, Founder, DEKA Research & Development

Pardes Headshot.June 2012.JPG

"Why not marry NIH’s talents and assets to the private sector assets and then invite people who have good ideas to come in so you can move the process."

Dr. Herb Pardes, Executive Vice Chairman of NewYork–Presbyterian Hospital; Former Director NIMH

Jessica Morris.jpg

"What really excites me about HARPA is it’s a really innovative approach that looks at today’s reality and tomorrow’s promise."

Jessica Morris, Co-founder of OurBrainBank

Dr. Matt Weiss.jpg

"I see HARPA helping us coordinate an effort amongst multiple people, institutions, and industry groups to come up with a plan, and to run it effectively together."

Dr. Matthew Weiss, Surgical Director, Johns Hopkins Liver and Pancreas Cancer Multidisciplinary Clinics


"90% of what Pharma takes out into that long pathway to bedside fails. And so all the capital that they put into clinical trials, into applied research, is down the drain. So this whole pathway from bench to bedside is not being treated carefully."

Dick Gephardt, Member of the House of Representatives 1976-2004

Dr. Steven Leach.jpg

"Only an entity like HARPA could bring together the biomedical and the engineer communities to fully exploit revolutions like the one currently occurring in nanotechnology."

Dr. Steven Leach, Director of Dartmouth's Norris Cotton Cancer Center

Karen Reeves.jpg

"HARPA wants to be time-limited. Wants answers soon. Not in the future. Soon. Smaller companies might be more nimble and able to streamline things better."

Karen Reeves, President & CMO, AZTherapies


"If HARPA existed today, I would instantly develop the technology to understand the prescribing practices of every doctor in this country who prescribes opioids, and be able to report on that on a quarterly basis with only a 30 day lag, so we can immediately spot which prescribers in this country are prescribing outside of CDC guidelines."

Gary Mendell, Founder & CEO, Shatterproof

Mike Stebbins.jpg

"We've got 9,000 human diseases. We have interventions for maybe 500 of these diseases. And the overwhelming majority of the other ones there are zero people working on treatments for them. There are people working on understanding the basics of it, but nobody working on treatments or cures for them… Until we start to go directly at that problem we're not going to get there."

Mike Stebbins, Former Assistant Director for Biotechnology at White House OSTP